A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses

Table 2

Demographic data of the 175 subjects (140 treated with different vitamin D doses according to the basal level and 35 with placebo) included in the study. For the main continuous baseline characteristics age, and BMI, an ANOVA was performed, and for the binomial baseline variable sex, we used a Cochran-Mantel-Haenszel test.

	Vitamin D treatment group					Placebo group					P value
	Group 1; (𝑛=40)	Group 2; (𝑛=40)	Group 3; (𝑛=40)	Group 4; (𝑛=20)	Subtotal; (𝑛=140)	Group 1; (𝑛=10)	Group 2; (𝑛=10)	Group 3; (𝑛=10)	Group 4; (𝑛=5)	Subtotal; (𝑛=35)
Age (years)
Mean ± SD	65.8±10.9	62.5±9.7	64.6±11.1	64.8±10.5	64.4±10.6	69.7±14.4	65.0±11.7	58.4±6.0	65.2±13.4	64.5±11.9	0.757
Min–max	51–89	50–84	51–88	52–87	50–89	50–90	50–85	51–71	50–81	50–90
Subject gender
Male: n (%)	14 (35.0)	15 (37.5)	17 (42.5)	5 (25.0)	51 (36.4)	5 (50.0)	5 (50.0)	4 (40.0)	1 (20.0)	15 (42.9)	0.473
Female: n (%)	26 (65.0)	25 (62.5)	23 (57.5)	15 (75.0)	89 (63.6)	5 (50.0)	5 (50.0)	6 (60.0)	4 (80.0)	20 (57.1)
BMI (kg/m²)
Mean ± SD	26.5±4.6	26.2±3.3	25.6±3.5	25.8±4.9	26.0±4.0	27.7±3.3	28.2±5.4	24.8±3.1	25.9±2.8	26.7±4.0	0.735
Min–max	19–35	20–34	19–34	19–37	19–37	22–32	20–35	19–30	24–31	19–35